Available Trials

---

• Breast
• Cholangiocarcinoma
• Endometrial
• Gynecological/Ovarian
• Hematology
• Lung - Non-Small Cell Lung
• Lung - Small Cell Lung
• Lymphoma
• Pancreas
• Solid Tumor
• STAR: Selected Trials Available for Accelerated Four Week Rollout

---

Breast

• USOR 22187 - Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03)

  A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001)
  

  Available at Arlington Heights, Niles

• USOR 22159 - Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1)

  A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)
  

  Available at Arlington Heights, Niles

---

Cholangiocarcinoma

• USOR 22123 - STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)

  Brightline-2: A Phase IIa/IIb, open-label, single-arm, multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic, MDM2 amplified, TP53 wild-type biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, or other selected solid tumours. (1403-0011)
  

  Available at Arlington Heights, Niles

---

Endometrial

• USOR 22242 - Ph3 Selin P53 Endo Carcinoma

  A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE, ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042)
  

  Available at Arlington Heights, Niles

---

Gynecological/Ovarian

• USOR 21270 - STAR Ph2 ZN-c3 Tumor DNA Repair CCGA

  A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ZN-c3-005| GOG 3066)
  

  Available at Arlington Heights, Niles

---

Hematology

• USOR 22311 - CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

  Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)
  

  Available at Niles, Arlington Heights

---

Lung - Non-Small Cell Lung

• USOR 21318 - STAR: PH1/3 Biomarker unresectable stg3 NSCLC

  A Phase I−III, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients Selected According to Biomarker Status, with Locally Advanced, Unresectable, Stage III Non−Small Cell Lung Cancer
  

  Available at Arlington Heights, Niles

• USOR 23235 - Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC

  A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)
  

  Available at Arlington Heights, Niles

• USOR 23074 - Ph3 SGN-B6A vs docetaxel NSCLC

  A randomized, phase 3, open-label study to evaluate SGN-B6A compared with docetaxel in adult subjects with previously treated non-small cell lung cancer (SGN-B6A-002)
  

  Available at Arlington Heights, Niles

• USOR 22229 - Ph3 Dato-Dxd Pembro PD-L1 < 50% NSCLC (TL07)

  A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or Without Platinum Chemotherapy, in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (DS1062-A-U303)
  

  Available at Arlington Heights, Niles

• USOR 21541 - Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50%

  A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS>=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (Tropion-Lung08)(Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)(DS1062-A-U304)
  

  Available at Arlington Heights, Niles

• USOR 22198 - STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR

  (FURMO-004) A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations
  

  Available at Arlington Heights, Niles

• USOR 22285 - MYLUNG Consortium Part 3: Observational Study

  Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Longitudinal Prospective RWE Study (MYLUNG Consortium Part 3: Observational Study)
  

  Available at Arlington Heights, Niles

• USOR 21498 - STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC

  A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)
  

  Available at Arlington Heights

• USOR 20412 - STAR Ph3 Adj Selp St1B/3 RET+ NSCLC

  A Placebo-Controlled, Double-Blinded, Randomized, Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET Fusion-Positive NSCLC (LIBRETTO-432)(J2G-MC-JZJX)
  

  Available at Arlington Heights, Niles

• USOR 20270 - Ph2 MRTX849 Pembro NSCLC KRAS

  A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation. (849-007) (Mirati Therapeutics)
  

  Available at Arlington Heights, Niles

• USOR 19044 - Ph 3 Durv vs. plbo SBRT NSCLC (PAC 4)

  D9103C00001: A Phase III, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, International Study of Durvalumab with Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with Unresected Stage I/II, Lymph-Node Negative, Non-Small Cell Lung Cancer. (PACIFIC-4/RTOG-3515)
  

  Available at Niles

---

Lung - Small Cell Lung

• USOR 23243 - Ph2 Randomized dose-optimization study of alisertib in patients with SCLC (PB-8237)

  A PHASE 2 STUDY OF ALISERTIB IN PATIENTS WITH EXTENSIVE SMALL CELL LUNG CANCER (PUMA-ALI-4201)
  

  Available at Arlington Heights, Niles

---

Lymphoma

• USOR 22041 - Ph2 Epco r/r B-Cell Lymph out pt

  A Phase 2, Open-Label Trial to Evaluate Safety of Epcoritamab monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 1-3a when Administered in the Outpatient Setting (M23-362)
  

  Available at Arlington Heights, Niles

• USOR 19062 - Ph 1b/3 Taze w/ R2 R/R Fol Lymph

  A Phase 1B/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study of Tazemetostat or Placebo in Combination with Lenalidomide Plus Rituximab in Subjects with Relapsed/Refractory Follicular Lymphoma (EZH-302)
  

  Available at Arlington Heights, Niles

---

Pancreas

• USOR 22133 - Ph1b/2 NabPac+ Gem +/- Botens Pancreatic 5FU +leuc Irin Oxal (FOLFIRINOX)

  A PHASE II RANDOMIZED, OPEN-LABEL, TRIAL OF NAB-PACLITAXEL +GEMCITABINE WITH OR WITHOUT BOTENSILIMAB (Agen1181) IN PATIENTS WITH METASTATIC PANCREATIC CANCER WHO HAVE PROGRESSED ON PRIOR 5FU + LEUCOVORIN+ IRINOTECAN +OXALIPLATIN (FOLFIRINOX)
  

  Available at Arlington Heights, Niles

• USOR 22123 - STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)

  Brightline-2: A Phase IIa/IIb, open-label, single-arm, multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic, MDM2 amplified, TP53 wild-type biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, or other selected solid tumours. (1403-0011)
  

  Available at Arlington Heights, Niles

---

Solid Tumor

• USOR 22311 - CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

  Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)
  

  Available at Niles, Arlington Heights

• USOR 19151 - STAR Ph1/2 MRTX849 Solids KRAS G12C

  A Phase 1/2, Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
  

  Available at Niles

---

STAR: Selected Trials Available for Accelerated Four Week Rollout

• USOR 21318 - STAR: PH1/3 Biomarker unresectable stg3 NSCLC

  A Phase I−III, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients Selected According to Biomarker Status, with Locally Advanced, Unresectable, Stage III Non−Small Cell Lung Cancer
  

  Available at Arlington Heights, Niles

• USOR 18263 - STAR Zanu in Acala Intolerant B-Cell

  A Phase 2, Multicenter, Single-Arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)
  

  Available at Arlington Heights, Niles

• USOR 20412 - STAR Ph3 Adj Selp St1B/3 RET+ NSCLC

  A Placebo-Controlled, Double-Blinded, Randomized, Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET Fusion-Positive NSCLC (LIBRETTO-432)(J2G-MC-JZJX)
  

  Available at Arlington Heights, Niles